COMPASS Pathways (NASDAQ:CMPS) and Agilon Health (NYSE:AGL) Financial Review

COMPASS Pathways (NASDAQ:CMPS) and Agilon Health (NYSE:AGL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for COMPASS Pathways and Agilon Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
COMPASS Pathways	1	1	7	0	2.67
Agilon Health	2	12	4	0	2.11

COMPASS Pathways currently has a consensus target price of $15.88, indicating a potential upside of 149.22%. Agilon Health has a consensus target price of $2.71, indicating a potential upside of 267.53%. Given Agilon Health’s higher possible upside, analysts clearly believe Agilon Health is more favorable than COMPASS Pathways.

Profitability

This table compares COMPASS Pathways and Agilon Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
COMPASS Pathways	N/A	-111.18%	-56.55%
Agilon Health	-5.24%	-75.92%	-18.35%

Insider & Institutional Ownership

46.2% of COMPASS Pathways shares are owned by institutional investors. 3.9% of COMPASS Pathways shares are owned by insiders. Comparatively, 3.6% of Agilon Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares COMPASS Pathways and Agilon Health”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
COMPASS Pathways	N/A	N/A	-$155.12 million	($2.72)	-2.34
Agilon Health	$6.06 billion	0.05	-$260.15 million	($0.75)	-0.98

COMPASS Pathways has higher earnings, but lower revenue than Agilon Health. COMPASS Pathways is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

COMPASS Pathways has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Agilon Health has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.

Summary

COMPASS Pathways beats Agilon Health on 7 of the 13 factors compared between the two stocks.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

About Agilon Health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.